Detalles de la búsqueda
1.
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
J Urol
; 209(4): 701-709, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36573926
2.
Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study.
Acta Oncol
; 61(1): 22-29, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34711121
3.
Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications.
Acta Oncol
; 60(11): 1499-1506, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34448678
4.
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Int J Cancer
; 146(5): 1435-1444, 2020 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31335987
5.
Whole-body diffusion-weighted magnetic resonance imaging for the detection of bone metastases and their prognostic impact in metastatic renal cell carcinoma patients treated with angiogenesis inhibitors.
Acta Oncol
; 59(7): 818-824, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297532
6.
Impact of concomitant acid suppressive therapy on pazopanib efficacy and dose reductions in patients with metastatic renal cell carcinoma.
Eur J Clin Pharmacol
; 76(9): 1273-1280, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32474662
7.
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Lancet Oncol
; 20(4): 581-590, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30827746
8.
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Lancet Oncol
; 20(10): 1370-1385, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31427204
9.
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Cancer
; 124(18): 3677-3683, 2018 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30307610
10.
Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Acta Oncol
; 57(4): 498-508, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-29095068
11.
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Gynecol Oncol
; 141(2): 386-401, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25940428
12.
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib.
BJU Int
; 118(6): 890-901, 2016 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-27417418
13.
Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Acta Oncol
; 55(3): 329-40, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26494607
14.
Incidence of bowel wall oedema on computed tomography exams and association with diarrhoea in renal cell carcinoma patients treated with sunitinib.
Eur Radiol
; 25(2): 375-9, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25163900
15.
Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib.
BJU Int
; 114(1): 81-9, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24215209
16.
Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Acta Oncol
; 53(10): 1413-22, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24874929
17.
VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Acta Oncol
; 53(1): 103-12, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23421954
18.
A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma.
Nat Med
; 2024 May 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38773341
19.
Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001.
J Exp Clin Cancer Res
; 43(1): 86, 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38504270
20.
Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Eur Urol
; 2024 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38290965